Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zuoqing San (ZQS) is a traditional Chinese medicine (TCM) formula used primarily for the management of ulcerative colitis, particularly in patients with large intestine damp-heat syndrome. It consists of 31 principal chemical constituents identified through liquid chromatography-mass spectrometry. The mechanism of action involves modulation of key inflammatory pathways and targets such as TNF, AKT1, IL6, IL1β, PTGS2, TP53, JUN, MMP9, CASP3, HIF1A, and BCL1. Pathway analysis indicates that Zuoqing San primarily impacts the TNF signaling pathway as well as NF-kB and IL-17 signaling pathways. Key active ingredients like oxymatrine and cynarin have demonstrated high affinity for TNF and IL1β respectively in molecular dynamics simulations[2]. Clinical studies have shown favorable outcomes in treating sigmoid ulcerative colitis with Zuoqing San[2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zuoqing San.